Taitacept for refractory or recurrent autoimmune encephalitis
Part of Brain & nervous system, Cancer, Immune system & allergy clinical trials.
This trial tests a new drug called Taitacept for people with autoimmune encephalitis (brain inflammation caused by the immune system) that has not improved with standard treatments or has returned. The goal is to see if Taitacept can help control symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 14 years or older
- You have been diagnosed with autoimmune encephalitis (with anti-NMDAR or anti-LGI1 antibodies) and your symptoms started within the last 9 months
- Your condition did not improve with steroids and rituximab or other immune-suppressing drugs, or it came back after treatment
- You are not pregnant, breastfeeding, or planning to have children during the trial
- You do not have other autoimmune diseases (like lupus or rheumatoid arthritis) or active infections (like tuberculosis or shingles)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if combining two medications (a B-cell depleting drug and daratumumab) can help people with autoimmune encephalitis who haven't improved with standard treatments.
This study is for people with autoimmune encephalitis, a condition where the immune system attacks the brain. It aims to collect information about this disease to learn more about it and how to treat it.
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests a new drug called telitacicept for people with rheumatoid arthritis (RA) that hasn't been controlled by multiple standard treatments. It aims to see if telitacicept can help reduce inflammation and improve symptoms.
This trial tests if rituximab, a targeted immune therapy, can help people with a newly identified antibody-linked condition. You may qualify if you have positive anti-vimentin antibodies in spinal fluid and signs of active disease such as new MRI lesions or worsening symptoms.
This trial tests a low dose of the drug blinatumomab to see if it can help adults with hard-to-treat autoimmune encephalitis or cerebellitis (brain inflammation caused by the immune system attacking the brain) who haven't gotten better with standard treatments. It aims to improve symptoms like memory loss, seizures, or coordination problems.
Hear when a new Anti-N-Methyl-D-Aspartate Receptor Encephalitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.